Drugs / GZ17-6.02
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06636123 | Feb 2025 → Apr 2027 expected | castration-resistant prostate carcinoma | Virginia Commonwealth University | Recruiting | No outcome recorded |
| Phase 1 | NCT03775525 | Mar 2019 → May 2023 | basal cell carcinoma, breast cancer, colorectal cancer, gastric carcinoma +6 | Genzada Pharmaceuticals USA, Inc. | Unknown | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-03-20 | Genzada Pharmaceuticals USA, Inc. | First Cancer Patient Receives Dose of Super-Enhancer Inhibitor GZ17-6.02 from Genzada Pharmaceuticals genzada.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GZ17-6.02 | “This single-arm phase Ib study will assess whether GZ17-6.02, a combination of curcumin, harmine, and isovanillin, delays radiographic progression of castration-resistant...” NCT06636123 ↗ |
| Route | Oral | “GZ17-6.02 given orally on a daily x 28 day schedule” NCT03775525 ↗ |